written on 18.07.2018



Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has acquired the global rights to Proleukin® (aldesleukin, recombinant interleukin-2) outside the United States from Novartis. Financial details have not been disclosed.

Proleukin® is licensed in around 20 countries around the world and is primarily indicated for use in metastatic renal cell carcinoma, as well as for metastatic melanoma in certain markets. In addition, Proleukin® is currently being investigated in clinical trials at varying dose levels and in combination with other licensed and developmental pharmaceutical products.

Clinigen will seek to revitalise sales of Proleukin® by working with Health Care Professionals to ensure its benefit to patients is well understood and by making the medicine available to those who need it through the Group’s global distribution network for both licensed and unlicensed supply. The Group is also investigating the opportunity to develop new dosage presentations and potential product combinations.

The acquisition of Proleukin® is a good fit with the Group’s current Commercial Medicines portfolio of products in the oncology and infectious disease therapy areas.

Shaun Chilton, Group Chief Executive Officer, Clinigen, said:

“This acquisition strengthens our offering in Commercial Medicines and brings our specialty pharma product portfolio to six. It demonstrates our strategy of acquiring global rights to assets with the aim of revitalising and returning them back to the broadest possible access, whilst also supporting their use in new and emerging treatment regimens.”

David Bryant, Chief Business Officer, Clinigen, said:

“Proleukin is an important medicine that has demonstrated complete responses in some patients, with evidence of cancer free survival over 15 years. We believe that its use in emerging treatment regimens will continue to help people fight cancer for years to come.”

The Group has also announced its year end trading update today – see separate press release.

– Ends –


Clinigen Group plc
Shaun Chilton, Group Chief Executive Officer
Julie Gosper, Head of Global Access
Tel: +44 (0) 1283 495010

Instinctif Partners
Melanie Toyne-Sewell / Alex Shaw / Deborah Bell
Tel: +44 (0) 20 7457 2020
Email: clinigen@instinctif.com

RBC Capital Markets – Joint Broker
Marcus Jackson / Elliot Thomas
Tel: +44 (0) 20 7653 4000